TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06484491

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Standard-dose intensity-modulated proton therapy (IMPT-60)
Description: The standard care group will receive 60.0 Gy (RBE) to the whole clinical target volume

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Dose-escalated intensity-modulated proton therapy (IMPT-74)
Description: Heterogeneous simultaneous integrated boost of 74.0 Gy (RBE) to primary tumor \>15mm away form mediastinal envelope, and 64.0 Gy (RBE) to primary tumor =\< 15mm away from mediastinal envelope. The rest of the clinical target volume, including affected lymph nodes, receives 60.0 Gy (RBE).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cisplatin or carboplatin + pemetrexed for induction chemotherapy, cisplatin + docetaxel for concurrent chemotherapy
Description: Induction course:~-Cisplatin (75 mg/m2) or carboplatin (AUC 6) + pemetrexed (500mg/m2).~Concurrent chemoradiotherapy:~* Weekly cisplatin (20mg/m2) + docetaxel (20mg/m2) on Mondays.~* Radiotherapy will be given for 5x5 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin or carboplatin + pemetrexed for induction chemotherapy, cisplatin + docetaxel for concurrent chemotherapy
Description: Induction course:~-Cisplatin (75 mg/m2) or carboplatin (AUC 6) + pemetrexed (500mg/m2).~Concurrent chemoradiotherapy:~* Weekly cisplatin (20mg/m2) + docetaxel (20mg/m2) on Mondays.~* Radiotherapy will be given for 5x5 days.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Immunotherapy: adjuvant durvalumab
Description: Adjuvant treatment will be given starting 1-6 weeks after chemoradiotherapy if no progression, good performance (PS 0-1), no other contra-indication for immunotherapy.~Doses:~* Start durvalumab 10 mg/kg 1x/14 days.~* If possible after 2 courses switch to 1500 mg flat dose 1x/4 wk.~* Continue for 12 months in total.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Immunotherapy: adjuvant durvalumab
Description: Adjuvant treatment will be given starting 1-6 weeks after chemoradiotherapy if no progression, good performance (PS 0-1), no other contra-indication for immunotherapy.~Doses:~* Start durvalumab 10 mg/kg 1x/14 days.~* If possible after 2 courses switch to 1500 mg flat dose 1x/4 wk.~* Continue for 12 months in total.
Study: NCT04946461

Intervention type: DRUG
Intervention: Dexamfetamine Sulfate 5 Mg Oral Tablet
Description: The dosage is set based on the recommendation of the practitioner. Dexamphetamine is administered twice a day, with an interval of 4 hours.

Intervention type: DRUG
Intervention: Dexamfetamine Sulfate 5 Mg Oral Tablet
Description: The dosage is set based on the recommendation of the practitioner. Dexamphetamine is administered twice a day, with an interval of 4 hours.

Intervention type: DRUG
Intervention: Lisdexamfetamine Dimesylate
Description: The dosage is set based on the recommendation of the practitioner. Lisdexamphetamine is only administered once a day.

Intervention type: DRUG
Intervention: Lisdexamfetamine Dimesylate
Description: The dosage is set based on the recommendation of the practitioner. Lisdexamphetamine is only administered once a day.

Intervention type: BIOLOGICAL
Intervention: blood samples
Description: The blood samples will be taken at set times: 0, 2, 4, 6, 9 and 12 (hours)

Intervention type: BIOLOGICAL
Intervention: blood samples
Description: The blood samples will be taken at set times: 0, 2, 4, 6, 9 and 12 (hours)
Study: NCT06212427

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: HMO supplement
Description: Liquid supplement containing 2 specific HMOs. Supplement will be given 3-4 times a day, not mixed with any feeding.
Study: NCT06008158

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Accelerated Partial Breast Irradiation
Description: Undergo APBI
Study: NCT05658003

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [177Lu]Lu-PSMA-617
Description: administered intravenously once every 6 weeks (1 cycle) for 6 cycles

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ARDT
Description: administered orally on a continuous basis, as per package insert and guidelines

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: [68Ga]Ga-PSMA-11
Description: single intravenous dose of approximately 150 MBq. Administered dose must not be lower than 111 MBq or higher than 259 MBq (3 - 7 mCi).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [68Ga]Ga-PSMA-11
Description: single intravenous dose of approximately 150 MBq. Administered dose must not be lower than 111 MBq or higher than 259 MBq (3 - 7 mCi).

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Best supportive care
Description: Best supportive/best standard of care as defined by the local investigator

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Best supportive care
Description: Best supportive/best standard of care as defined by the local investigator
Study: NCT05273970

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Behavioral testing under intracranial monitoring
Description: After standard of care surgery to implant the electrodes is complete and patients have have recovered satisfactorily from the procedure, they will be asked to perform some computer based tasks to answer questions about pretend financial decisions, pay attention to certain images, watch videos, look at images, listen to sounds, or move a joystick.
Study: NCT04927052

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Revanesse Shape + with Lidocaine
Description: Revanesse Shape + with Lidocaine. Participants had 1 cheek treated with Revanesse Shape + with Lidocaine

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Revanesse Shape + with Lidocaine
Description: Revanesse Shape + with Lidocaine. Participants had 1 cheek treated with Revanesse Shape + with Lidocaine

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Juvederm Voluma with Lidocaine.
Description: Juvederm Voluma with Lidocaine. Participants had 1 cheek treated with Juvederm Voluma with Lidocaine

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Juvederm Voluma with Lidocaine.
Description: Juvederm Voluma with Lidocaine. Participants had 1 cheek treated with Juvederm Voluma with Lidocaine
Study: NCT05245058

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SPH5030 tablets
Description: SPH5030 tablets orally once or twice daily.
Study: NCT06569446

Intervention type: OTHER
Intervention: There is no intervention. This a qualitative study to explore barriers to rectal irrigation
Description: This will involve semi-structured, open-ended questions about hypothesized barriers to rectal irrigation where the interviewer will ask a pre-determined number of questions and the participants will answer which will further initiate discussion allowing new themes to emerge. After the entire list of barriers is discussed, participants will be asked if they have any new barriers to add which have not been discussed. All new barriers identified will be added to the hypothesized barriers list for the next focused group sessions. Focused group sessions will continue until no new barriers are found in two consecutive sessions (thematic saturation).~9.2 Phase - 2 includes Cognitive Interviews This will involve semi-structured, open-ended questions about barriers to rectal irrigation identified during focused group sessions where the interviewer will ask pre-determined number of questions for individual participants to answer.

Intervention type: OTHER
Intervention: There is no intervention. This a qualitative study to explore barriers to rectal irrigation
Description: This will involve semi-structured, open-ended questions about hypothesized barriers to rectal irrigation where the interviewer will ask a pre-determined number of questions and the participants will answer which will further initiate discussion allowing new themes to emerge. After the entire list of barriers is discussed, participants will be asked if they have any new barriers to add which have not been discussed. All new barriers identified will be added to the hypothesized barriers list for the next focused group sessions. Focused group sessions will continue until no new barriers are found in two consecutive sessions (thematic saturation).~9.2 Phase - 2 includes Cognitive Interviews This will involve semi-structured, open-ended questions about barriers to rectal irrigation identified during focused group sessions where the interviewer will ask pre-determined number of questions for individual participants to answer.
Study: NCT06571903

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Teaching from videos
Description: Teaching from videos for independent study
Study: NCT06571929

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: INTERACT
Description: INTERACT is an individualized, task-specific training program that includes environmental enrichment, natural and augmented realities, and active training.
Study: NCT06570330

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: SuperHMO
Description: Super HMO Prebiotic Mix: five major types of human milk oligosaccharides including 2'-Fucosyllactose (2'-FL), Lacto-N-tetraose (LNT), Lacto-N-neotetraose (LNnT), 6'-Sialyllactose (6'SL), and 3'-Sialyllactose (3'SL)

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Non-GMO corn Maltodextrin, Rapid Absorption
Description: he composition and absorption properties are similar to the investigational product and will be given in the same dosage (2.1g/day for days 1-5 and increasing to 4.2 g/day for days 6-30) and route of administration as the investigational product.
Study: NCT05512819

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 20-valent pneumococcal conjugate vaccine
Description: 20-valent pneumococcal conjugate vaccine

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: 13-valent pneumococcal conjugate vaccine
Description: 13-valent pneumococcal conjugate vaccine
Study: NCT06243250

Intervention type: DIAGNOSTIC_TEST
Intervention: Hyperpolarized 13C-MRI
Description: Metabolic MRI using IV injection of hyperpolarized \[1-13C\]pyruvate.

Intervention type: DIAGNOSTIC_TEST
Intervention: Hyperpolarized 13C-MRI
Description: Metabolic MRI using IV injection of hyperpolarized \[1-13C\]pyruvate.

Intervention type: DIAGNOSTIC_TEST
Intervention: Hyperpolarized 13C-MRI
Description: Metabolic MRI using IV injection of hyperpolarized \[1-13C\]pyruvate.
Study: NCT06117631

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Centering Parenting
Description: See Arm description.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Bright by Text
Description: See Arm description.
Study: NCT06042387

Intervention type: GENETIC
Intervention: Blood or saliva sample collection
Description: Blood or saliva sample \& clinical data collection

Intervention type: GENETIC
Intervention: Blood or saliva sample collection
Description: Blood or saliva sample \& clinical data collection
Study: NCT05550974

Intervention type: DEVICE
Intervention: Minimally Invasive Surgery
Description: gynecological, urologic, thoracic, plastic and reconstructive and ENT etc. endoscopic and laparoscopic surgical procedures

Intervention type: DEVICE
Intervention: Minimally Invasive Surgery
Description: gynecological, urologic, thoracic, plastic and reconstructive and ENT etc. endoscopic and laparoscopic surgical procedures
Study: NCT06479980

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Single Session Narrative Therapy
Description: Single-session narrative psychotherapy intervention is an evidence-based strategy on a stepped care continuum that can assist patients in accessing care when they most need it and can lead to the most effective utilization of scarce resources. It offers a transdiagnostic, strengths, solution-oriented, and non-pathologizing intervention to address patients' behavioral health needs.
Study: NCT05091762

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: exercise
Description: Upper limb resistance training with blood flow obstruction

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: exercise
Description: Upper limb resistance training with blood flow obstruction

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: exercise
Description: Upper limb resistance training with blood flow obstruction
Study: NCT05337436

Intervention type: BIOLOGICAL
Intervention: Lymphatic drainage
Description: Biological determination in plasma:

Intervention type: BIOLOGICAL
Intervention: Total and ionized magnesium
Description: Total and ionized magnesium

Intervention type: BIOLOGICAL
Intervention: Total and ionized calcium
Description: Total and ionized calcium
Study: NCT05227144

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ORIC-533
Description: ORIC-533 once daily in consecutive 28-day cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ORIC-533
Description: ORIC-533 once daily in consecutive 28-day cycles
Study: NCT05997771

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Personal Nutrition Advisor
Description: The study intervention will be the use of the PNA data analysis tool during remote nutritional counselling sessions delivered by certified dietitians, also referred to as PNA-assisted remote nutritional counselling.
Study: NCT06121856

Intervention type: DEVICE
Intervention: VerioVue Enhancements BGMS
Description: Blood glucose monitoring system
Study: NCT05262725

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Values-based Behavioral Activation
Description: Initially, patients complete a values assessment in which they identify personal values in various life domains. With the assistance of a clinician, patients set incremental behavior goals to move their daily actions to better align with their self-reported values. Goal completion allows the patient to achieve outcomes consistent with recovery, and they potentially experience enjoyment, self-efficacy, and confidence as they progress through the treatment.
Study: NCT06016192

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Aerobic Exercise Training
Description: Physical activity performed as controlled aerobic exercise training on ergometer

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Aerobic Exercise Training
Description: Physical activity performed as controlled aerobic exercise training on ergometer
Study: NCT05432141

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: sIPV vaccine /DTaP vaccine
Description: All subjects received 3 doses of sIPV vaccines and 3 doses of DTaP vaccines. Subjects recommended intramuscular injection. The best site for intramuscular injection is the anterolateral middle thigh for infants and the deltoid muscle for children.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: sIPV vaccine /Hepatitis A inactivated vaccine /MMR vaccine
Description: All subjects will receive 1 dose of sIPV and 2 doses of hepatitis A inactivated vaccine/or 1 dose of attenuated hepatitis A vaccine and 1 dose of MMR vaccine.Subjects recommended intramuscular injection. The best site for intramuscular injection is the anterolateral middle thigh for infants and the deltoid muscle for children.
Study: NCT06516484

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Romiplostim
Description: Enrolled patients were given roprostin (20 µg/kg subcutaneously once weekly) for at least 3 months, with discontinuation of roprostin for platelet counts ≥50 x 10\^9/L and continuation of roprostin for platelet counts \<50 x 10\^9/L. Responders were continued to 6 months. Responders continue to use the drug until 6 months.
Study: NCT05770869

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ALIBIRD mHealth platform
Description: Use of a mHealth platform to follow-up and empower cancer patients in the self-management of their own health.
Study: NCT05454007

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Step length asymmetry training
Description: Participants will engage in four, five-minute periods of step symmetry training during session 2. This training uses established sensorimotor adaptation-based methods (e.g. split-belt treadmill walking, walking with unilateral leg weighting) to elicit motor aftereffects of more equal step lengths. Two minute sitting rest breaks will be given between training blocks or at the participant's request. A video recording will be taken of the first and final two minutes of training.
Study: NCT05321927

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Trancutaneous Electrical Nerve Stimulation
Description: Transcutaneous Electrical Nerve Stimulation produces an electrical current to stimulate the nerves for therapeutic purposes. continuous high frequency (≥ 50 Hz) stimulation for 5 minutes followed by high frequency (≥ 50 Hz) bursts with 9 pulses per burst for the last 5 minutes, with a stimulation/rest ratio of 1:2.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Trancutaneous Electrical Nerve Stimulation
Description: Transcutaneous Electrical Nerve Stimulation produces an electrical current to stimulate the nerves for therapeutic purposes. continuous high frequency (≥ 50 Hz) stimulation for 5 minutes followed by high frequency (≥ 50 Hz) bursts with 9 pulses per burst for the last 5 minutes, with a stimulation/rest ratio of 1:2.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Strength training
Description: Three training sessions for 10 minutes per muscle, per week, for four weeks in total.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Strength training
Description: Three training sessions for 10 minutes per muscle, per week, for four weeks in total.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham stimulation
Description: Continuous stimulation at 1 Hz for 2 seconds, then no stimulation for 10 seconds. This will alternate for 10 minutes. The intensity equals the intensity that is just felt by the individual.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Sham stimulation
Description: Continuous stimulation at 1 Hz for 2 seconds, then no stimulation for 10 seconds. This will alternate for 10 minutes. The intensity equals the intensity that is just felt by the individual.
Study: NCT06130917

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Multisystem Exercise
Description: Proprioception: Seated ankle ball. Single leg stance with support and with extension of knees. Single leg stance (hip extension) with support and with extension' of knees.~Muscle strengthening: Seated alternate double knee lifts with weights, chair stands. Seated alternate kicks with weigh. Hip extension standing with support with weights.~Balance Training Seated alternate weight shifts. Seated calf and toe raise. Heel raise with support.. Crossover with support Reaction time Seated alternate touches to front. Seated alternate touches to back. Seated alternate touches to side. Seated alternate touches to 3 steps (forward, side, backward).

Intervention type: OTHER
Group type: OTHER
Intervention: Conventional Treatment
Description: ROM exercises Passive ROM exercise of hip. Passive ROM exercise of knee. Passive ROM exercise of ankle Muscle strengthening Seated alternate double knee lifts with weights. chair stands. Seated alternate kicks with weigh. Hip extension standing with support with weights.~Balance Seated alternate weight shifts. Seated calf and toe raise. Heel raise with support. Crossover with support Stretching exercises Stretching exercise of hamstring. Stretching exercise of quadriceps. Stretching exercise of calf muscle
Study: NCT05596942

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Albumin Channa Striata Extract
Description: This study is a randomized controlled trial of 42 patients at the ICU of Dr. Moewardi General Hospital. The control group received 20 grams of human albumin on the first day and the study group received 15 grams of Channa striata extract daily for two days. Subsequently, eNOS, NLR and PLR are measured before and three days after treatment, and the examiners compare the three markers statistically.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Albumin Channa Striata Extract
Description: This study is a randomized controlled trial of 42 patients at the ICU of Dr. Moewardi General Hospital. The control group received 20 grams of human albumin on the first day and the study group received 15 grams of Channa striata extract daily for two days. Subsequently, eNOS, NLR and PLR are measured before and three days after treatment, and the examiners compare the three markers statistically.
Study: NCT06192797

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: HAIC
Description: administration of gemcitabine and oxaliplatin via the tumor feeding arteries every 3 weeks.
Study: NCT05091762

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: exercise
Description: Upper limb resistance training with blood flow obstruction
Study: NCT06192797

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenvatinib plus pucotenlimab
Description: lenvatinib (8mg, qd) plus pucotenlimab (200mg, q3w)
Study: NCT05175001

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Diprospan
Description: Diprospan combined with ropivacaine in ultrasound-guided thoracic paravertebral nerve block
Study: NCT05959200

Intervention type: DEVICE
Group type: OTHER
Intervention: Serafilcon A toric contact lenses
Description: Silicone hydrogel contact lenses for the optical correction of refractive ametropia (myopia or hyperopia with astigmatism)

Intervention type: DEVICE
Group type: OTHER
Intervention: Serafilcon A toric contact lenses
Description: Silicone hydrogel contact lenses for the optical correction of refractive ametropia (myopia or hyperopia with astigmatism)

Intervention type: DEVICE
Group type: OTHER
Intervention: Senofilcon A toric contact lenses
Description: Silicone hydrogel contact lenses for the optical correction of refractive ametropia (myopia or hyperopia with astigmatism)

Intervention type: DEVICE
Group type: OTHER
Intervention: Senofilcon A toric contact lenses
Description: Silicone hydrogel contact lenses for the optical correction of refractive ametropia (myopia or hyperopia with astigmatism)

Intervention type: DEVICE
Group type: OTHER
Intervention: CLEAR CARE
Description: Hydrogen peroxide-based contact lens cleaning and disinfecting solution

Intervention type: DEVICE
Group type: OTHER
Intervention: CLEAR CARE
Description: Hydrogen peroxide-based contact lens cleaning and disinfecting solution
Study: NCT05843760

Intervention type: OTHER
Intervention: personal information form
Description: undergraduate student(participants) will be asked; age, weight, height, smoking and alcohol use, and headache.

Intervention type: OTHER
Intervention: headache-specific questionnaires
Description: ıd migraine test, numeric rate scale, hit-6 headache impact test, headache information form

Intervention type: OTHER
Intervention: Questionnaires for assessing biopsychosocial status
Description: hospital anxiety depression, Discomfort Intolerance Test, pittsburgh sleep quality index, fatigue severity scale, self compassion scale, Body Awareness Questionarre, cervical range of motion, İnternational Physical Activity Questionnaire, 12-Item Short-Form Health Survey
Study: NCT05175001

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Ropivacaine
Description: Only ropivacaine in ultrasound-guided thoracic paravertebral nerve block